Background
Spinal muscular atrophy (SMA) is a severe neuromuscular disease (NMD) caused by deficiency of survival motor neuron (SMN) protein, due to homozygous loss of
SMN1 gene function. SMA demonstrates a broad range in clinical disease severity, which is reflected by the distinction of 4 types in the clinical classifications system [
1,
2]. Improved understanding of the natural history of SMA has facilitated improvements of standards for supportive care and clinical trial design [
1,
3‐
6]. Respiratory complications, such as hypoventilation and impaired secretion clearance, are the most important cause of morbidity and mortality in SMA [
1,
2] but respiratory outcome measures have not yet been used as primary outcomes in clinical trials. This is, at least partially, caused by a lack of reference data [
7,
8].
Respiratory muscle weakness in SMA is characterized by a rather unique pattern with predominant weakness of (mainly expiratory) intercostal muscles and relative sparing of (inspiratory) diaphragm function [
9,
10]. Respiratory muscle weakness is associated with decreased pulmonary compliance, lung underdevelopment, decreased ability to cough, and it may ultimately lead to respiratory failure [
11].
Improved insights into the natural history of respiratory muscle strength could guide therapeutic management [
12], improve timing of supportive care [
1], and facilitate its use as an outcome measure for longer-term follow-up of patients or treatment efficacy assessments [
2,
7,
13,
14]. Tests of respiratory muscle strength may detect respiratory insufficiency earlier than more frequently used measurements of expiratory lung function [e.g. forced vital capacity (FVC)]. Longitudinal studies on the decline of respiratory muscle strength have been performed in other NMDs but not in SMA [
15]. Therefore, we studied the natural history of respiratory muscle strength and assessed differences between SMA types in a large, population-based, treatment-naïve cohort of SMA patients.
Discussion
Here, we present natural history data on the longitudinal course of respiratory muscle strength in treatment-naïve patients with SMA. We show that there are clear differences in respiratory muscle strength between SMA types with a progressive decline. In general, measurements of respiratory muscle strength are most affected in the more severe SMA types. Based upon our data, particularly PEF may be a suitable outcome measure for follow-up of patients with SMA.
Progressive respiratory muscle weakness is the most important cause of morbidity and mortality in patients with SMA [
1,
2] and contributes to the increasing dependency on mechanical ventilation of patients with SMA types 1 and 2 [
34]. The absence of respiratory function measures as a primary outcome in the pivotal clinical trials of recently introduced genetic therapies for SMA is at least partially explained by the scarcity of reference data [
4,
5]. Recent studies on the effect of nusinersen treatment in adult patients have focussed on motor scores and indicate that identification of the ‘ideal’ outcome parameter, reflecting both worsening or improvement in motor function at all grades of disease severity, might not be feasible. This has contributed to the advice that future studies should focus on the long-term effect of nusinersen on other motor-related functions such as ventilation [
35]. We recently published a large body of natural history data on lung function in SMA [
8], but these spirometry endpoints may be affected by factors that are independent of respiratory muscle dysfunction [
36]. Respiratory muscle strength may be an even more appropriate outcome measure [
36].
PE
max and PI
max were severely affected in SMA types 1c–3a. PE
max may be the most suitable outcome of these two, as expiratory muscle function is predominantly affected in patients with SMA [
9,
10]. Interestingly, PE
max was low in patients with SMA type 3a from early ages on, whilst we have previously shown that lung volumes in these patients remain normal at least until (early) adulthood [
8]. Based on these data, we believe PE
max is a sensitive screening parameter to detect respiratory muscle weakness in SMA patients.
Our findings corroborate the results of some previous cross-sectional studies indicating decreased PE
max and PI
max with normal lung volumes in patients with SMA types 2 and 3 [
15,
21], although different results in two other small studies have also been reported [
9,
37].
SNIP has been proposed as an alternative or complementary test to PI
max. It measures inspiratory strength and normal values exclude inspiratory muscle weakness [
32,
38]. In our cohort, SNIP was abnormally lowered in virtually all patients without significant differences between SMA types, although a trend of decreasing SNIP values with more severe phenotypes was present. Our observations are in accordance with the recent work of Kapur [
37]. Although SNIP is easy to perform, it may underestimate inspiratory muscle strength in case of nasal obstruction or severe respiratory muscle weakness [
38], which may be present from young ages onwards in patients with SMA types 1 and 2. Even though strong correlations between SNIP, PI
max and vital capacity have been shown [
28], we believe it may be less suited to discriminate between SMA types or as an outcome measure for longitudinal follow-up.
In the absence of bronchial obstruction, PEF reflects maximal expiratory flow [
12,
39]. We observed differences at baseline between SMA types and a rather linear decline of PEF in most types over time, resembling the course of FVC in patients with SMA [
8]. As the average annual PEF decline did not differ significantly between SMA types, SMA types are primarily separated by differences already present at baseline or occurring very early in life. The observed pattern of relative stabilization in adults with SMA types 2 and 3a could be caused by relative disease stabilization, but we believe it is more likely the consequence of either a floor effect due to difficulties with quantification of very low PEF values or loss to follow-up of most severely affected patients due to death or initiation of invasive mechanical ventilation. Based upon our findings, PEF may be used as an outcome measure for SMA in future studies, as has also been suggested for Duchenne Muscular Dystrophy [
40].
Coughing is essential for airway clearance and requires coordinated use of both inspiratory and expiratory muscles, which can be assessed by PCF [
28]. PCF in SMA patients had previously only been studied in small cohorts [
37]. In our study, nearly all patients had a PCF < 270 L/min. In SMA type 1c and a large number of patients with type 2 PCF was even < 160 L/min. Since low PCF is associated with an increased occurrence of RTIs, PCF could represent a clinically meaningful endpoint for trials.
Our work has important strengths and expands the scarce natural history data on respiratory strength in patients with SMA. First, we investigated a range of measurements reflecting respiratory muscle strength in a large population-based cohort, covering a broad spectrum of SMA severity and a wide age range. Secondly, the large cohort allowed for analyses to assess differences between SMA types. We studied several tests of respiratory muscle weakness as it is known that combining these tests increases diagnostic precision [
41]. Finally, to overcome the risk of including inaccurate data from weaker patients, especially young children, professionals experienced in performing these tests in pediatric and adult patients with NMDs conducted all tests.
The generally broad confidence intervals around both intercepts and slopes are a limitation of our work. It reflects the uncertainty of the predicted longitudinal patterns. This can partly be explained by the inability of young children to reliably perform these tests, but also the limited number of observations at older ages for some of the SMA types. The limited number of elderly patients in our cohort is possibly partly explained by SMA-related death or loss to follow-up. However, we do not believe that this changes our conclusion that the general pattern of respiratory muscle strength is one of decline over time. Finally, our study lacks an assessment of possible confounders, such as severity of (corrected) scoliosis, use of airway clearance techniques, or mechanical ventilation. However, we consider this less important as our study focuses on the natural history of SMA with treatment according to the standards of care [
1,
6].
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.